ABCL Q2 2023 Earnings — AbCellera Biologics Inc. Revenue & Financial Results | Market Cap Arena

ABCLAbCellera Biologics Inc.

$1B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10M-78.1% YoY

Gross Profit

$10M100.0% margin

Operating Income

-$51M-511.0% margin

Net Income

-$31M-303.6% margin

EPS (Diluted)

$-0.11

QoQ Revenue Growth

-17.5%

Cash Flow

Operating Cash Flow

$20M

Free Cash Flow

-$8M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.5B

Total Liabilities

$342M

Stockholders' Equity

$1.2B

Cash & Equivalents

$180M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10M	$46M	-78.1%
Gross Profit	$10M	$41M	-75.3%
Operating Income	-$51M	-$8M	-512.1%
Net Income	-$31M	-$7M	-349.9%

Revenue Segments

Research Fees

$10M98%

License

$226,0002%